Fig. 4: Structures of complexes, ACE2 footprint, mutation sites and Fab footprints on RBD.
From: Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
a–d Side views (relative to human torso analogy7) of RBDs for the crystal structures of Delta-RBD/BA.4/5-1/EY6A20, Delta-RBD/BA.4/5-2/Beta-4921, Delta-RBD/BA.4/5-9 and Delta-RBD/BA.4/5-35, respectively. RBD is shown as a grey surface representation with BA.4/5 mutation sites in magenta, Fabs as ribbons with HC in red and LC in blue. e–j Surface representation of RBD viewed from the top e Residues on the ACE2 footprint shown in green. f RBD with all the mutation sites of variants tested against BA.4/5 mAbs in magenta and ACE2 footprint marked by a black outline. g–j BA.4/5-1, BA.4/5-2, BA.4/5-9 and BA.4/5-35 footprints are shown in cyan, respectively, and the ACE2 footprint is marked by a black outline.
